A Phase 1b Study to Assess the Safety Profile, Pharmacokinetics, and Anti-VEGF Activity of PTC299 in Patients With Advanced Cancer.

Trial Profile

A Phase 1b Study to Assess the Safety Profile, Pharmacokinetics, and Anti-VEGF Activity of PTC299 in Patients With Advanced Cancer.

Suspended
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2012

At a glance

  • Drugs Docetaxel; PTC 299
  • Indications Cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors PTC Therapeutics
  • Most Recent Events

    • 06 Apr 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 27 May 2010 Planned number of patients changed from 42 to 76 as reported by ClinicalTrials.gov.
    • 27 May 2010 Planned end date changed from 1 Jun 2010 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top